Market cap
$1.67B
Shares out
89.9M

Braveheart Bio Inc. (BRVE) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 10 wire items for BRVE, including 4 13D/G filings, 3 SEC filings and 2 press releases and news items. The most recent was published Nov 16, 2026.

Braveheart Bio is a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy ('HCM') and other serious cardiovascular diseases. Our lead product candidate, BHB-1893, is a next-generation oral small-molecule cardiac myosin inhibitor, that we are developing for the treatment of obstructive HCM and non-obstructive HCM. Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity. BHB-1893 was initially discovered and developed by Jiangsu Hengrui Pharmaceuticals Co in China. We in-licensed BHB-1893 pursuant to an exclusive license agreement with Hengrui.

BRVE rankings

News · 26 weeks10+100%
2026-05-24: 02026-05-31: 02026-06-07: 02026-06-14: 02026-06-21: 02026-06-28: 02026-07-05: 02026-07-12: 02026-07-19: 02026-07-26: 02026-08-02: 02026-08-09: 02026-08-16: 02026-08-23: 02026-08-30: 02026-09-06: 02026-09-13: 02026-09-20: 02026-09-27: 02026-10-04: 02026-10-11: 02026-10-18: 02026-10-25: 02026-11-01: 32026-11-08: 52026-11-15: 2
2026-05-242026-11-15
Mix1090d
  • 13D/G4(40%)
  • SEC Filings3(30%)
  • Other2(20%)
  • Earnings1(10%)
Activity · 52 weeks105 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news

Latest news

10 items

BRVE FAQ

7 questions
  • What does Braveheart Bio Inc. do?
    Braveheart Bio is a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy ('HCM') and other serious cardiovascular diseases. Our lead product candidate, BHB-1893, is a next-generation oral small-molecule cardiac myosin inhibitor, that we are developing for the treatment of obstructive HCM and non-obstructive HCM. Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity. BHB-1893 was initially...
  • What is the latest news on BRVE?
    In the last 30 days Quantisnow tracked 10 wire items for BRVE: 4 13D/G filings, 3 SEC filings, 2 press releases and news items and 1 earnings update. The most recent was published on November 16, 2026.
  • Where does BRVE stock trade?
    Braveheart Bio Inc. (BRVE) is listed on NASDAQ.
  • What sector and industry is BRVE in?
    Braveheart Bio Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.
  • When did Braveheart Bio Inc. go public?
    Braveheart Bio Inc. (BRVE) completed its IPO in 2026.
  • What companies are similar to BRVE?
    Notable peers in the same industry include MRK (Merck & Company Inc.), LLY (Eli Lilly and Company), NVO (Novo Nordisk A/S), ABT (Abbott Laboratories), JNJ (Johnson & Johnson). Compare BRVE side-by-side with any of them on Quantisnow.
  • How can I track BRVE on Quantisnow?
    Quantisnow aggregates Braveheart Bio Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BRVE to receive live email and push alerts on every new disclosure.

Is something on this page wrong, or out of date? Request a change